Bryan Texas – June 3, 2025 – Sano Women’s Health, a biotechnology company focused on innovative treatments for underserved women's health conditions, announced today it has raised funding through a convertible note and crowdfunding campaign on StartEngine to support its Phase 2 clinical trials for a first-in-class treatment targeting recurrent vulvovaginal candidiasis (RVVC).
RVVC is a chronic and often debilitating condition affecting up to 8% of women globally, marked by repeated episodes of vaginal yeast infections that significantly impact quality of life. Sano’s lead candidate, OCF001, is designed to offer a novel therapeutic approach with improved efficacy and safety over current antifungal therapies.
"This funding represents a critical milestone for Sano Women’s Health and for the millions of women living with RVVC who deserve better treatment options," said James Leif Smith, President of Sano Women’s Health. "With support from our investors, we are well-positioned to advance OCF001 into Phase 2 Clinical Studies and continue our mission to bring patient-centric, science-driven solutions to the forefront of women’s health."
The financing round is a recognition of the urgent need for innovation in the RVVC space and the strong scientific foundation behind Sano’s therapeutic platform. Sano has received qualified infectious disease product (QIDP) and FastTrack designations from the FDA to advance this much needed product.
Phase 2 trials are expected to begin in December 2025, with “proof of concept” results anticipated by February 2026.
For more information, please contact:
Janice Miles, DO
Co-CEO
Sano Women’s Health
jmiles@sanochemicals.com | 855-384-7266
www.sanowomenshealth.com
James Leif Smith
President and Co-CEO
Sano Women’s Health
jsmith@sanochemicals.com | 855-384-7266
www.sanowomenshealth.com